Journal of General Internal Medicine

, Volume 27, Issue 9, pp 1159–1164 | Cite as

Association Between Race, Depression, and Antiretroviral Therapy Adherence in a Low-Income Population with HIV Infection

  • Meg C. Kong
  • Milap C. Nahata
  • Veronique A. Lacombe
  • Eric E. Seiber
  • Rajesh Balkrishnan
Original Research

Abstract

Background

Racial disparities exist in many aspects of HIV/AIDS. Comorbid depression adds to the complexity of disease management. However, prior research does not clearly show an association between race and antiretroviral therapy (ART) adherence, or depression and adherence. It is also not known whether the co-existence of depression modifies any racial differences that may exist.

Objective

To examine racial differences in ART adherence and whether the presence of comorbid depression moderates these differences among Medicaid-enrolled HIV-infected patients.

Design

Retrospective cohort study.

Setting

Multi-state Medicaid database (Thomson Reuters MarketScan®).

Participants

Data for 7,034 HIV-infected patients with at least two months of antiretroviral drug claims between 2003 and 2007 were assessed.

Main Measures

Antiretroviral therapy adherence (90 % days covered) were measured for a 12-month period. The main independent variables of interest were race and depression. Other covariates included patient variables, clinical variables (comorbidity and disease severity), and therapy-related variables.

Key Results

In this study sample, over 66 % of patients were of black race, and almost 50 % experienced depression during the study period. A significantly higher portion of non-black patients were able to achieve optimal adherence (≥90 %) compared to black patients (38.6 % vs. 28.7 %, p < 0.001). In fact, black patients had nearly 30 % decreased odds of being optimally adherent to antiretroviral drugs compared to non-black patients (OR = 0.70, 95 % CI: 0.63–0.78), and was unchanged regard less of whether the patient had depression. Antidepressant treatment nearly doubled the odds of optimal ART adherence among patients with depression (OR = 1.92, 95 % CI: 1.12–3.29).

Conclusions

Black race was significantly associated with worse ART adherence, which was not modified by the presence of depression. Under-diagnosis and under-treatment of depression may hinder ART adherence among HIV-infected patients of all races.

KEY WORDS

HIV adherence depression race Medicaid 

References

  1. 1.
    Kraut-Becher J, Eisenberg M, Voytek C, Brown T, Metzger DS, Aral S. Examining racial disparities in HIV. J Acquir Immune Defic Syndr. 2008;47(Suppl 1):S20–S27.PubMedGoogle Scholar
  2. 2.
    Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520–529.PubMedCrossRefGoogle Scholar
  3. 3.
    Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA. 1999;281:2305–2315.PubMedCrossRefGoogle Scholar
  4. 4.
    Cunningham WE, Anderson RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270–1281.PubMedCrossRefGoogle Scholar
  5. 5.
    Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96.PubMedCrossRefGoogle Scholar
  6. 6.
    Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Reports (Washington, DC: 1974), June 2002. 117(3):233–251; discussion 231–232.Google Scholar
  7. 7.
    CDC. HIV/AIDS Surveillance Report, 2007. Vol. 19. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at http://www.cdc.gov/hiv/surveillance/resources/reports/2007report/index.htm. Accessed February 20, 2012.
  8. 8.
    Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2009. National Vital Statistics Report, vol. 57, no. 14. Available at http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf. Accessed February 20, 2012.
  9. 9.
    Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2001;26:82–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the multicenter AIDS cohort study. AIDS. 2004;18:683–688.PubMedCrossRefGoogle Scholar
  11. 11.
    Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. JIDS. 2005;38:320–328.Google Scholar
  12. 12.
    Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among white, Hispanic, and black men in the MACS cohort. J Acquir Immune Defic Syndr. 2009;52:290–293.PubMedCrossRefGoogle Scholar
  13. 13.
    Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–395.PubMedCrossRefGoogle Scholar
  14. 14.
    Golin C, Liu H, Hays R, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–765.PubMedCrossRefGoogle Scholar
  15. 15.
    Thrasher AD, Earp JAL, Golin CE, et al. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on Efavirenz-Containing regimens for initial HIV therapy. J Acquir Immune Defic Syndr. 2007;46:547–554.PubMedCrossRefGoogle Scholar
  17. 17.
    Weiser SD, Riley ED, Ragland K, Hammer G, Clark R, Bangsberg DR. Brief report: factors associated with depression among homeless and marginally housed HIV Infected men in San Francisco. J Gen Intern Med. 2006;21:61–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Asch S, Kilbourne A, Gifford A, et al. Underdiagnosis of depression in HIV. J Gen Intern Med. 2003;18:450–460.PubMedCrossRefGoogle Scholar
  19. 19.
    Yun LW, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:432–438.PubMedCrossRefGoogle Scholar
  20. 20.
    Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a Meta-analysis. J Gen Intern Med. 2011;26:1175–1182.PubMedCrossRefGoogle Scholar
  21. 21.
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–2107.PubMedCrossRefGoogle Scholar
  22. 22.
    Shacham E, Nurutdinova D, Satyanarayana V, et al. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care STDS. 2009;23:949–955.PubMedCrossRefGoogle Scholar
  23. 23.
    Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401–409.PubMedGoogle Scholar
  24. 24.
    Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285:1466–1474.PubMedCrossRefGoogle Scholar
  25. 25.
    Burack JH, Barrett DC, Stall RD, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568–2573.PubMedCrossRefGoogle Scholar
  26. 26.
    Leserman J, Petitto JM, Perkins DO, et al. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. a 2-year follow-up study. Arch Gen Psychiatry. 1997;54:279–285.PubMedCrossRefGoogle Scholar
  27. 27.
    Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:384–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.PubMedCrossRefGoogle Scholar
  29. 29.
    Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–1769.PubMedCrossRefGoogle Scholar
  30. 30.
    Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418–428.PubMedCrossRefGoogle Scholar
  31. 31.
    Robinson MJ, Qaqish RB. Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatr Clin North Am. 2002;25:149–175.PubMedCrossRefGoogle Scholar
  32. 32.
    Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156:101–107.PubMedGoogle Scholar
  33. 33.
    Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Jul 8, 2008. pp. 1–98. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed February 20, 2012.
  34. 34.
    CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed February 20, 2012.
  35. 35.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.PubMedCrossRefGoogle Scholar
  36. 36.
    Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911–925.PubMedCrossRefGoogle Scholar
  37. 37.
    Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167–73.PubMedCrossRefGoogle Scholar
  38. 38.
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMedGoogle Scholar
  39. 39.
    Martin M, Del CE, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263–1268.PubMedCrossRefGoogle Scholar
  40. 40.
    Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23(5):601–611.PubMedCrossRefGoogle Scholar
  41. 41.
    Lima VD, Harrigan R, Murry M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371–2380.PubMedCrossRefGoogle Scholar
  42. 42.
    Boulware LE, Cooper LA, Ratner LE, et al. Race and trust in the health care system. Public Health Rep. 2003;118:358–65.PubMedGoogle Scholar
  43. 43.
    Das AK, Olfson M, McCurtis HL, et al. Depression in African Americans: breaking barriers to detection and treatment. J Fam Pract. 2006;55:30–39.PubMedGoogle Scholar
  44. 44.
    Melfi CA, Croghan TW, Hanna MP, et al. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry. 2000;16:16–21.CrossRefGoogle Scholar
  45. 45.
    Dunlop DD, Song J, Lyons JS, Mannheim LM, Chang RW. Racial/ethnic differences in rates of depression among pre-retirement adults. Am J Public Health. 2003;93:1945–1952.PubMedCrossRefGoogle Scholar
  46. 46.
    Kessler RC, Berglund P, Demler O, et al. National comorbidity survey replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.PubMedCrossRefGoogle Scholar
  47. 47.
    Walkup JT, Boyer CA, Kellermann SL. Reliability of Medicaid claims files for use in psychiatric diagnoses and service delivery. Adm Policy Ment Health. 2000;27:129–139.PubMedCrossRefGoogle Scholar
  48. 48.
    Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care. 2001;39:1188–1202.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2012

Authors and Affiliations

  • Meg C. Kong
    • 1
  • Milap C. Nahata
    • 1
  • Veronique A. Lacombe
    • 1
  • Eric E. Seiber
    • 2
  • Rajesh Balkrishnan
    • 3
  1. 1.College of PharmacyOhio State UniversityColumbusUSA
  2. 2.College of Public HealthOhio State UniversityColumbusUSA
  3. 3.College of Pharmacy and School of Public HealthUniversity of MichiganAnn ArborUSA

Personalised recommendations